June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] READ MORE
June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] READ MORE
March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize in lupus research because it was there that she felt she could be of greatest value. “There were so many unknowns in lupus with all its complexity. Here was a disease primarily affecting young women […] READ MORE
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY. A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] READ MORE
February 14, 2022 Being a kid isn’t always easy, but growing up with lupus makes it a much harder challenge. That’s why Harvard University’s Associate Professor Dr. Joyce Chang has a special place in her heart for these kids and chose to focus her career on their care. In honor of American Heart Month, we […] READ MORE
January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE
November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] READ MORE
August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […] READ MORE
June 8, 2021 The annual European Congress of Rheumatology (EULAR 2021) brought much good news of potential new treatments for systemic lupus erythematosus (SLE). Following are highlights: Rituximab Plus Belimumab Taking belimumab after rituximab may help lupus according to data from the BEAT-LUPUS trial presented at the 2021 EULAR Virtual Congress by the trial lead investigator […] READ MORE
Updated March 11, 2022 Neuropsychiatric lupus affects 80-90% of people with lupus. In a video series hosted by the Young Leaders Board of the Lupus Research Alliance, Dr. Meggan Mackay explains How to know if you have neuropsychiatric lupus and offers ways to improve cognitive health. Dr. Mackay also describes a clinical trial she is […] READ MORE
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] READ MORE
October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […] READ MORE
